Work

Follow the “DOTs”: Vδ1+ γδ T cells as effectors of cancer immunotherapy

Year: 2026

Type: article

Abstract: Cancer immunotherapy has mostly relied on conventional T cells to achieve success in a limited set of tumor types. A promising avenue to expand the repertoire of cancers effectively treated through immune intervention is to mobilize other anti-tumor effectors, such as γδ T cells. Among these, the Vδ1+ subset commonly predominates within peripheral tissues and within tumors, typically associating with good prognosis. In this Found in Translation, we discuss how to leverage the biological properties of Vδ1+ γδ T cells for cancer immunotherapy, with special focus on the delta one T (DOT) cell approach.

Source: The Journal of Experimental Medicine

DOI: 10.1084/jem.20252289

Authors: Bruno Silva-Santos, Sofia Mensurado, Rafael Blanco-Domínguez, Adrian C. Hayday

Institutions: University of Lisbon, Gulbenkian Institute for Molecular Medicine, King's College London, The Francis Crick Institute

Language: English

Topic: T-cell and B-cell Immunology

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Takeda Development Center Americas, European Molecular Biology Organization, Ministério da Ciência, Tecnologia e Ensino Superior, Foundation for Science and Technology